Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982104 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5549318 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL31519543 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982109 | 1.00 | PNP (0.76) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL23982120 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982387 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL176347 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL21562191 | 0.88 | PNP (0.79) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982393 | 0.88 | PNP (0.62) | PNPLMNATP53HTTPDE4D | |
| SCHEMBL5982391 | 0.88 | PNP (0.62) | PNPLMNATP53HTTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596858-B2 | Dissolving 2,6-diaminopurine derivatives in an aprotic solvent mixture and reacting with organic nitrite and metal halide (Lewis acids) | RELIABLE BIOPHARMACEUTICAL, INC. | 2003-07-22 | — | — | US | disclosed |
| US-6498241-B1 | 2-deoxy-isoguanosines isosteric analogues and isoguanosine derivatives as well as their synthesis | ROCHE DIAGNOSTICS GMBH (DE) | 2002-12-24 | — | — | US | disclosed |
| US-20020052492-A1 | Process for the production of 2-halo-6-aminopurine derivatives | RELIABLE BIOPHARMACEUTICAL, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6252061-B1 | REACTING 2,6-DIAMINOPURINE WITH ORGANIC NITRITE AND METAL HALIDE | RELIABLE BIOPHARMACEUTICAL, INC. | 2001-06-26 | — | — | US | disclosed |
| US-6147199-A | 2-deoxy-isoguanosines isoteric analogues and isoguanosine containing oligonucleotides | BOEHRINGER MANNHEIM (DE) | 2000-11-14 | — | — | US | disclosed |
| EP-0626853-B1 | USE OF SUBSTITUTED ADENINE DERIVATIVES FOR TREATING MULTIPLE SCLEROSIS | SCRIPPS RESEARCH INST (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0776211-A4 | 2-HALO-2'-DEOXYADENOSINE TREATMENT FOR HISTIOCYTOSIS | SCRIPPS RESEARCH INST (US) | 1999-12-08 | — | — | EP | disclosed |
| EP-0776211-A1 | 2-HALO-2'-DEOXYADENOSINE TREATMENT FOR HISTIOCYTOSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-06-04 | — | — | EP | disclosed |
| US-5541164-A | Such as cladribine, to treat e.g. rheumatoid arthritis and multiple sclerosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-07-30 | — | — | US | disclosed |
| US-5510336-A | ADMINISTERING LOWER DOSAGES FOR SIDE EFFECT REDUCTION | SCRIPPS RESEARCH INSTITUTE, THE | 1996-04-23 | — | — | US | disclosed |
| EP-0355135-B1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1993-08-04 | — | — | EP | disclosed |
| US-5106837-A | Administering 2-halo-2'-deoxyadenosine such as cladribine; treating autohemolytic anemia | THE SCRIPPS RESEARCH INSTITUTE (US) | 1992-04-21 | — | — | US | disclosed |
| US-4997926-A | Viricides | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-03-05 | — | — | US | disclosed |
| EP-0364559-A4 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS | — | 1991-01-09 | — | — | EP | disclosed |
| EP-0364559-A1 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS. | SCRIPPS CLINIC RES (US) | 1990-04-25 | — | — | EP | disclosed |
| EP-0355135-A4 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES. | SCRIPPS CLINIC RES (US) | 1990-04-09 | — | — | EP | disclosed |
| EP-0355135-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-02-28 | — | — | EP | disclosed |
| WO-1989008658-A1 | SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-09-21 | — | — | WO | disclosed |
| WO-1989004662-A1 | ADENOSINE DEAMINASE-STABLE ANTI-RETROVIRAL NUCLEOSIDES | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1989-06-01 | — | — | WO | disclosed |
| US-4719295-A | ANTIMICROBIAL, ANTIVIRAL, ANTILEUKEMIA | WARNER-LAMBERT COMPANY (US) | 1988-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052492-A1 | Process for the production of 2-halo-6-aminopurine derivatives | TPMT, NUDT1, DCTD | PNP 7/4885LMNA 4608/4885TP53 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.